Imatinib, better known as Gleevec, was hailed as a "miracle" cancer drug when it entered the market in the early 2000s. Though it has been highly successful at treating early-stage chronic myeloid leukemia (CML)—a rare ...
Jun 1, 2022
0
150
The body's innate immune system, active from birth, is the first line of defense against viruses and other pathogens that cause disease. Using vaccination as an example, after receiving a vaccine, pain, redness, or swelling ...
May 25, 2022
0
179
Compared with placebo and azacitidine, the combination of ivosidenib and azacitidine prolongs event-free survival for patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are ineligible for induction chemotherapy, ...
Apr 21, 2022
0
13
Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukemia cells. By rewiring the inner workings ...
Apr 19, 2022
0
74
During the first nine months of the COVID-19 pandemic, pediatric cancer patients from lower- and middle-income countries faced a higher risk of all-cause mortality than those in high-income countries, according to data presented ...
Apr 11, 2022
0
54
Researchers at the Department of Oncology-Pathology have published a paper in Nature Communications where they created a cell line resource dataset and analysis tool that could be used to identify the traits that make specific ...
Mar 30, 2022
0
19
New research has begun to unravel the mystery of why a particular form of leukemia in infants has defied efforts to improve outcomes, despite significant improvements in treating older children. Scientists from the Wellcome ...
Mar 14, 2022
0
92
In order to better treat patients diagnosed with acute myeloid leukemia (AML), the pathological processes and also existing subtypes of the disease must be better understood. With the help of proteome and genome analysis, ...
Mar 4, 2022
0
27
Some genetic mutations linked to leukemia are less than useful guides to making treatment decisions for patients. A new study from the University of Wisconsin–Madison suggests a group of clinical signs that can be paired ...
Feb 22, 2022
0
70
Acute myeloid leukemia (AML) is an aggressive cancer of white blood cells with few effective targeted therapies available to treat it. Cold Spring Harbor Laboratory (CSHL) Professor Christopher Vakoc and former graduate student ...
Jan 11, 2022
0
92
